HOUSTON, TX / ACCESSWIRE / December 12, 2019 / SpinalCyte, LLC, a Texas-based regenerative medicine company, is proud to have Chief Executive Officer, Pete O’Heeron named one of the 30 Best CEOs of 2020 by Silicon Review magazine. His in-depth profile interview can be found here: https://thesiliconreview.com/magazine/profile/pete-o-heeron-ceo-through-continued-discovery-and-development-in-the-lab/
In part, the interview delves into SpinalCyte discoveries using human dermal fibroblasts to regenerate tissue. Mr. O’Heeron leads a scientific team which is pursuing a cure for degenerative disc disease along with multiple sclerosis, chronic traumatic encephalopathy (CTE) and other disease pathways using its first product offering, CybroCell. SpinalCyte’s current intellectual property portfolio now includes 174 U.S. and international patents issued and/or pending which are focused on the clinical use of fibroblasts.
“To be honored with a Top 3 spot on this list is a credit to the work of our scientists and the breakthroughs they are developing in the lab”, commented Pete O’Heeron. “Our work with fibroblasts is beginning to gain the attention of the medical community and this honor will highlight the work of our team.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 60 U.S. and international issued patents and has filed for an additional 110+ patents pending and issued across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.
Clinical Contact: firstname.lastname@example.org
SOURCE: SpinalCyte, LLC
View source version on accesswire.com: